|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neitzel LT, Neitzel CD, Magee KL and
Malafa MP: Angiogenesis correlates with metastasis in melanoma. Ann
Surg Oncol. 6:70–74. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warso MA, Maniotis AJ, Chen X, Majumdar D,
Patel MK, Shilkaitis A, Gupta TK and Folberg R: Prognostic
significance of periodic acid-Schiff-positive patterns in primary
cutaneous melanoma. Clin Cancer Res. 7:473–477. 2001.PubMed/NCBI
|
|
5
|
Liu WB, Xu GL, Jia WD, Li JS, Ma JL, Chen
K, Wang ZH, Ge YS, Ren WH, Yu JH, et al: Prognostic significance
and mechanisms of patterned matrix vasculogenic mimicry in
hepatocellular carcinoma. Med Oncol. 28:(Suppl 1). S228–S238. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirakawa K, Wakasugi H, Heike Y, Watanabe
I, Yamada S, Saito K and Konishi F: Vasculogenic mimicry and
pseudo-comedo formation in breast cancer. Int J Cancer. 99:821–828.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seftor EA, Meltzer PS, Kirschmann DA,
Pe'er J, Maniotis AJ, Trent JM, Folberg R and Hendrix MJ: Molecular
determinants of human uveal melanoma invasion and metastasis. Clin
Exp Metastasis. 19:233–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Schaft DW, Seftor RE, Seftor EA,
Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW and
Hendrix MJ: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rice C and Huang LE: From antiangiogenesis
to hypoxia: Current research and future directions. Cancer Manag
Res. 3:9–16. 2010.PubMed/NCBI
|
|
10
|
Sun M, Han J, Duan J, Cui Y, Wang T, Zhang
W, Liu W, Hong J, Yao M, Xiong S and Yan X: Novel antitumor
activities of Kushen flavonoids in vitro and in vivo. Phytother
Res. 21:269–277. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeh CB, Hsieh MJ, Hsieh YH, Chien MH,
Chiou HL and Yang SF: Antimetastatic effects of norcantharidin on
hepatocellular carcinoma by transcriptional inhibition of MMP-9
through modulation of NF-kB activity. PLoS One. 7:e310552012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY,
Zhao ZM, Lu XS and Fan YZ: Norcantharidin inhibits tumor growth and
vasculogenic mimicry of human gallbladder carcinomas by suppression
of the PI3-K/MMPs/Ln-5γ2 signaling pathway. BMC Cancer. 14:1932014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
An WW, Wang MW, Tashiro S, Onodera S and
Ikejima T: Norcantharidin induces human melanoma A375-S2 cell
apoptosis through mitochondrial and caspase pathways. J Korean Med
Sci. 19:560–566. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin Y, Zhang Q, Lee S, Zhong WL, Liu YR,
Liu HJ, Zhao D, Chen S, Xiao T, Meng J, et al: Doxycycline reverses
epithelial-to-mesenchymal transition and suppresses the
proliferation and metastasis of lung cancer cells. Oncotarget.
6:40667–40679. 2015.PubMed/NCBI
|
|
15
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
16
|
Hofmann-Wellenhof R, Woltsche-Kahr I,
Smolle J and Kerl H: Clinical and histological features of poor
prognosis in cutaneous metastatic melanomas. J Cutan Pathol.
23:199–204. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Higa GM and Abraham J: Biological
mechanisms of bevacizumab-associated adverse events. Expert Rev
Anticancer Ther. 9:999–1007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gille J: Antiangiogenic cancer therapies
get their act together: Current developments and future prospects
of growth factor- and growth factor receptor-targeted approaches.
Exp Dermatol. 15:175–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grothey A and Galanis E: Targeting
angiogenesis: Progress with anti-VEGF treatment with large
molecules. Nat Rev Clin Oncol. 6:507–518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun
W: Norcantharidin: A potential antiangiogenic agent for gallbladder
cancers in vitro and in vivo. Int J Oncol. 40:1501–1514.
2012.PubMed/NCBI
|
